Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor

被引:41
作者
Abu Lila, Amr S. [1 ]
Doi, Yusuke [1 ]
Nakamura, Kazuya [1 ]
Ishida, Tatsuhiro [1 ]
Kiwada, Hiroshi [1 ]
机构
[1] Univ Tokushima, Dept Pharmacokinet & Biopharmaceut, Subdiv Biopharmaceut Sci, Inst Hlth Biosci, Tokushima 7708505, Japan
关键词
Anticancer therapy; Sequential administration; Anticancer drug; Oxaliplatin; PEG-coated cationic liposomes; DRUG-DELIVERY; ANTITUMOR EFFICACY; IN-VIVO; TARGETED NANOMEDICINES; THERAPEUTIC-EFFICACY; LOADED LIPOSOMES; DOXORUBICIN; IMMUNOLIPOSOMES; PACLITAXEL; CISPLATIN;
D O I
10.1016/j.jconrel.2009.10.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Recently, we designed a PEG-coated cationic liposome to achieve dual targeting delivery of I-OHP to both tumor endothelial cells and tumor cells in a solid tumor. The targeted liposomal I-OHP formulation showed an efficient antitumor activity in a murine tumor model after three sequential liposomal I-OHIP injections. This led us to assume that prior dosing with liposomes might enhance the intra-tumoral accumulation of a subsequent dose, and hence improve the therapeutic efficacy of entrapped I-OHP. The present study shows that while a single liposomal I-OHP injection does not enhance tumor accumulation of subsequent test-PEG-coated cationic liposomes, two sequential injections of liposomal I-OHP do. Cumulative cytotoxic effects of I-OHP delivered by PEG-coated cationic liposomes led to deep diffusion of a subsequent dose of liposomal I-OHP in solid tumor presumably as a result of the enlarged intra-tumoral interstitial space. Our study suggests that sequential injections of a targeted liposonnal anticancer drug is of significant clinical and practical importance in enhancing the delivery of adequate quantities of anticancer agents into intractable solid tumors, and thereby may achieve a significant anticancer efficacy. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:167 / 173
页数:7
相关论文
共 42 条
  • [1] Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model
    Abu Lila, Amr S.
    Kizuki, Shinji
    Doi, Yusuke
    Suzuki, Takuya
    Ishida, Tatsuhiro
    Kiwada, Hiroshi
    [J]. JOURNAL OF CONTROLLED RELEASE, 2009, 137 (01) : 8 - 14
  • [2] Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model
    Abu-Lila, Amr
    Suzuki, Takuya
    Doi, Yusuke
    Ishida, Tatsuhiro
    Kiwada, Hiroshi
    [J]. JOURNAL OF CONTROLLED RELEASE, 2009, 134 (01) : 18 - 25
  • [3] Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates
    Allen, TM
    Mumbengegwi, DR
    Charrois, GJR
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3567 - 3573
  • [4] Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line
    Arnould, S
    Guichard, S
    Hennebelle, I
    Cassar, G
    Bugat, R
    Canal, P
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (08) : 1215 - 1226
  • [5] Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC
    Asai, Tomohiro
    Miyazawa, Souichiro
    Maeda, Noriyuki
    Hatanaka, Kentaro
    Katanasaka, Yasufumi
    Shimizu, Kosuke
    Shuto, Satoshi
    Oku, Naoto
    [J]. CANCER SCIENCE, 2008, 99 (05) : 1029 - 1033
  • [6] Au J L, 1999, AAPS PharmSci, V1, pE8
  • [7] Clinical aspects of drug delivery to tumors
    Au, JLS
    Jang, SH
    Wientjes, MG
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 78 (1-3) : 81 - 95
  • [8] BARTLETT GR, 1959, J BIOL CHEM, V234, P469
  • [9] Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
    El Bayoumil, TamerA.
    Torchilin, Vladimir P.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1973 - 1980
  • [10] Eliaz RE, 2001, CANCER RES, V61, P2592